Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell

计划入组 135 人 · 首次发布于 2017 年 6 月 8 日

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

计划入组 550,000 人 · 首次发布于 2021 年 12 月 17 日

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

计划入组 241,981 人 · 首次发布于 2021 年 10 月 11 日

DPP4-Fc

SGLT1/SGLT2/DPP4 Inhibitor(Tonghua Dongbao Pharmaceutical Co., Ltd.)

Begelomab

DPP PHARMACEUTICALS PTY LTD

Australia

GLP-1 Receptor Agonists Show Lower Risk for MACE and VTE in Lupus and Type 2 Diabetes Patients Compared to DPP4 Inhibitors

DPP4 Inhibitor Shows Promise in Rejuvenating Lung Stem Cells for Idiopathic Pulmonary Fibrosis

GLP-1 Receptor Agonists Show Survival Benefit in Cancer Patients with Type 2 Diabetes